AU2155297A - Nucleoside compositions containing paracellular absorption enhancers - Google Patents

Nucleoside compositions containing paracellular absorption enhancers

Info

Publication number
AU2155297A
AU2155297A AU21552/97A AU2155297A AU2155297A AU 2155297 A AU2155297 A AU 2155297A AU 21552/97 A AU21552/97 A AU 21552/97A AU 2155297 A AU2155297 A AU 2155297A AU 2155297 A AU2155297 A AU 2155297A
Authority
AU
Australia
Prior art keywords
compositions containing
absorption enhancers
paracellular absorption
nucleoside compositions
nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21552/97A
Other languages
English (en)
Inventor
Laurence Francis Lacey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2155297A publication Critical patent/AU2155297A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU21552/97A 1996-03-13 1997-03-12 Nucleoside compositions containing paracellular absorption enhancers Abandoned AU2155297A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9605293 1996-03-13
GBGB9605293.1A GB9605293D0 (en) 1996-03-13 1996-03-13 Medicaments
PCT/EP1997/001236 WO1997033565A1 (fr) 1996-03-13 1997-03-12 Compositions nucleosides renfermant des activateurs d'absorption paracellulaire

Publications (1)

Publication Number Publication Date
AU2155297A true AU2155297A (en) 1997-10-01

Family

ID=10790327

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21552/97A Abandoned AU2155297A (en) 1996-03-13 1997-03-12 Nucleoside compositions containing paracellular absorption enhancers

Country Status (3)

Country Link
AU (1) AU2155297A (fr)
GB (1) GB9605293D0 (fr)
WO (1) WO1997033565A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
WO2009092002A1 (fr) * 2008-01-17 2009-07-23 Duquesne University Of The Holy Spirit Préparations médicamenteuses antirétrovirales pour le traitement d'enfants exposés au vih/sida
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104383541A (zh) 2011-10-21 2015-03-04 艾伯维公司 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法
DK2583680T1 (da) 2011-10-21 2015-01-19 Abbvie Inc Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN103908466A (zh) * 2012-12-29 2014-07-09 安徽贝克生物制药有限公司 齐多夫定、拉米夫定胶囊剂及其制备方法
RU2587782C1 (ru) * 2015-01-19 2016-06-20 Общество с ограниченной ответственностью "Трейдсервис" Стабильная фармацевтическая композиция ламивудина
CA3022119A1 (fr) 2016-04-28 2017-11-02 Emory University Compositions therapeutiques a base de nucleotides et nucleosides contenant un alcyne et utilisations associees

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
JP2831030B2 (ja) * 1989-05-12 1998-12-02 学校法人城西大学 ３’‐アジド‐３’デオキシチミジンを有効成分とする経皮投与製剤用組成物
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
EP0576605A4 (en) * 1991-03-19 1994-06-08 Vithal J Rajadhyaksha Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers
JPH07500114A (ja) * 1991-12-13 1995-01-05 ジー．ディー．サール　アンド　カンパニー 経皮吸収性アジドチミジン
GB9418530D0 (en) * 1994-09-14 1994-11-02 Glaxo Group Ltd Medicaments
GB9517022D0 (en) * 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
GB9605293D0 (en) 1996-05-15
WO1997033565A1 (fr) 1997-09-18

Similar Documents

Publication Publication Date Title
AU3005197A (en) Ink compositions having improved latency
AU1804597A (en) Radiation curable ink composition
EP0781819A3 (fr) Compositions d'encre pour l'impression par jet
EP0934956A4 (fr) Composition durcissable
AU8680698A (en) Polynucleotide compositions
PL336980A1 (en) Pharmaceutic composition
PL330223A1 (en) Pharmaceutic composition
AU3982697A (en) Ink composition
GB9804469D0 (en) Antiviral composition
AU6550394A (en) Novel pyrimidine nucleosides
AU6237898A (en) Defoaming compositions
AU2155297A (en) Nucleoside compositions containing paracellular absorption enhancers
AUPN933396A0 (en) Non-aqueuos oral-drench compositions containing avermectin compounds
PL329919A1 (en) Diclophenac-based pharmaceutic compositions
PL334006A1 (en) Lyophilisable pharmaceutic compositions
AU4384297A (en) Antiviral compositions
AU3462497A (en) Absorption enhancer
AU1595997A (en) Thienoxazinone derivatives useful as antiviral agents
AUPP366198A0 (en) Anfo composition
AU2036997A (en) Compositions containing starch excipients
IL115254A0 (en) Pharmaceutical compositions containing paracellular absorption enhancers
EP0934984A4 (fr) Composition durcissable
AU1470497A (en) Triazine containing compounds useful as antiviral agents
AU1504097A (en) Antiperspirant composition
AU3032997A (en) Antiperspirant composition